Relmada Therapeutics (RLMD) Treasury Shares (2016 - 2026)

Relmada Therapeutics (RLMD) has 7 years of Treasury Shares data on file, last reported at $8.0 million in Q1 2026.

• On a quarterly basis, Treasury Shares rose 817.41% year-over-year to $8.0 million in Q1 2026; TTM through Mar 2026 was $8.0 million, a 817.41% increase from a year earlier, with the FY2025 full-year figure at $5.9 million, up 325.29% from the prior year.
• Treasury Shares for Q1 2026 stood at $8.0 million, up from $5.9 million in the prior quarter.
• Over the last five years, Treasury Shares for RLMD reached as high as $8.0 million in Q1 2026 and fell as low as $750908.0 in Q2 2025.
• Historically, Treasury Shares has averaged $2.7 million across 5 years, with a median of $1.7 million in 2024.
• Across the five-year window, Treasury Shares plunged 54.86% in 2025 and soared 817.41% in 2026, its largest moves.
• Year by year, Treasury Shares stood at $3.0 million in 2022, then slipped by 21.34% to $2.4 million in 2023, then plunged by 41.94% to $1.4 million in 2024, then surged by 325.29% to $5.9 million in 2025, then soared by 36.19% to $8.0 million in 2026.
• Per Business Quant data, the three most recent Treasury Shares figures were $8.0 million in Q1 2026, $5.9 million in Q4 2025, and $750908.0 in Q3 2025.